Abstract: The invention is provides a composition for sustained delivery of a biologically active agent comprising a biologically active mixture and a controlled release formulation. The composition protects the biologically active agent from being destroyed by the controlled release composition. The biologically active mixture includes the biologically active agent and a pharmaceutically acceptable protective carrier. The controlled release formulation includes a pharmaceutically acceptable, biodegradable, matrix forming material that is substantially insoluble in aqueous or body fluids and a pharmaceutically acceptable organic solvent. The biologically active mixture is combined with the controlled release formulation to form an emulsion, the delivery composition, which is then administered to a patient. The protective carrier can be an aqueous substance, a non-aqueous substance or a combination of both. The matrix forming material can be a polymeric material, a non-polymeric material or a combination of both.

Abstract: The present invention relates to a method for removing bile acids from a patient and certain polymers of use in the method. The method comprises the step of administering to the patient a therapeutically effective amount of a polymer composition which includes a a poly(diallylamine) polymer which is substituted with hydrophobic groups. The hydrophobic groups can be a substituted or unsubstituted, straight chain or branched C3–C24-alkyl group, an aralkyl group or an aryl group.

Abstract: Methods for tissue repair are provided employing a matrix comprising a biocompatible, bioerodable polymer, said polymer comprising a thermoplastic lactide-containing terpolymer of monomer units derived from lactic acid, glycolic acid, and either caprolactone or valerolactone, which has a water solubility of about 0.01 to about 500 mg/mL at about 25° C. and adhesive strength of about 600 to about 150,000 Pa and applying the matrix to a tissue defect. The matrix or adhesive can further comprise a filler or a bioactive agent, or both.

Abstract: The invention relates to processes for preparing, and pharmaceutical compositions of, modafinil dosage forms for oral administration. The dosage forms include a mixture of coarse and fine particles of modafinil. The process for preparing modafinil oral dosage forms includes forming a dosage form that includes about 7%–25% by weight of modafinil particles having diameters greater than 220 ?m and about 75%–93% by weight of modafinil particles having diameters less than 220 ?m.

Abstract: A thickener-rheology modifier system for use in hair care and skin care compositions comprising: a) a hydrophobically modified, alkali-soluble copolymer thickener comprising an aqueous emulsion copolymer of: i) from about 5 to 70 weight percent of ?, ? ethylenically unsaturated carboxylic acid monomer of the formula: where R is H and R1 is H, C1–C4 alkyl, or —CH2COOX; R is —COOX and R1 is H or —CH2COOX; and R is CH3 and R1 is H, C1–C4 alkyl or —CH2COOX; and X is H or C1–C4 alkyl; ii) from about 10 to 90 weight percent of a nonionic, copolymerizable, ?, ? ethylenically unsaturated monomer of the formula: CH2?CYZ where Y is H or CH3 and Z is where R is C1 to C4 alkyl; and iii) from about 1 to 30 weight percent of a hydrophobically modified, ?, ? ethylenically unsaturated carboxylic acid monomer of the formula: where R is an alkyl group of 6 to 22 carbon atoms or an alkaryl of 8 to 22 carbon atom, x is an average number of from about 6 to 200, y is an average number of from

Abstract: An invention for polymerizing or crosslinking a prepolymer using a water soluble, thermal polymerization initiator is disclosed. The prepolymer mixed with the initiator is injected or placed into an animal's body, and heat is applied over the site of the injection to polymerize the polymer. This transdermal thermal polymerization system can be used for drug delivery of bioactive agents in tissue engineering applications in which living cells are delivered.

Abstract: A transdermal drug delivery device involving a macromonomer-containing acrylate or methacrylate copolymer, a softener, and a drug. Also a pressure sensitive skin adhesive involving a macromonomer containing acrylate or methacrylate copolymer and a softener.

Abstract: Irritation upon injection of a formulation containing propofol is reduced or substantially eliminated by administering a stable, sterile, and antimicrobial aqueous dispersion comprising a water-insoluble microdroplet matrix of mean diameter from about 50 nm to about 1000 nm consisting essentially of about 1% to about 15% of propofol, up to about 7% of a propofol-soluble diluent, and about 0.8% to about 4% of a surface stabilizing amphiphilic agent. The aqueous phase includes a pharmaceutically acceptable water-soluble polyhydroxy tonicity modifier. The propofol-containing dispersion is devoid of additional bactericidal or bacteriostatic preservative agents.

Abstract: A method for producing a colored cosmetic composition having inorganic pigments resistant to agglomeration in an oil-in-water emulsion. The method includes the following: preparing an oil dispersion by adding inorganic pigments directly to an oil; preparing an aqueous base that includes water; combining the oil dispersion and aqueous base; and partitioning the inorganic pigments between the oil and the aqueous phase under controlled conditions, for example, hydrophile-lipophile balance, agitation time and speed, and cooling rate. The present invention provides a process to easily disperse iron-oxide pigments, even black iron-oxide pigments, in oil-in-water emulsions. The present invention provides colored cosmetic compositions that have excellent properties, such as smoothness, adhesion to skin, uniform color, ease of removal, smudge resistance and non-oiliness.

Abstract: The present invention provides a controlled release device for sustained or pulsatile delivery of pharmaceutically active substances for a predetermined period of time. This invention further provides such device in which sustained or pulsatile delivery is obtained by the unique blend and intimate mixture of pharmaceutically active substances with a microbial polysaccharide and uncrosslinked linear polymer and optionally a crosslinked polymer and/or lipophillic polymer and/or saturated polyglycolyzed glyceride. The invention also provides a process for the manufacture of such devices and pharmaceutical compositions containing the same.

Abstract: Urinary incontinence is alleviated in a mammal by administering to the mammal a urinary incontinence alleviating amount of dextromethorphan, dextrorphan, their mixtures and/or pharmaceutically acceptable salts, alone or in combination with a pharmacologically active agent such as an anticholinergic, sympathomimetic, tricyclic antidepressant, antispasmodic, direct-acting smooth muscle relaxant, estrogen, compound having estrogen-like activity, or any combination of the foregoing.

Abstract: Disclosed are electrostatically-sprayable topical compositions, more particularly topical emulsion compositions, and methods of treating the skin by electrostatic application of such compositions. In one aspect the composition comprises an insulating external phase comprising one or more insulating materials and a conductive internal phase comprising one or more conductive materials. The compositions preferably also contain one or more particulate materials to be deposited on the skin, e.g., pigments, inert absorbents and the like.

Abstract: Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs.

Abstract: A controlled absorption diltiazem pellet formulation for oral administration comprises a core having diltiazem or a pharmaceutically acceptable salt thereof as the active ingredient. The core is surrounded by a coating which has only a single layer which is comprised of a relatively major proportion of talc and relatively minor proportion of sodium lauryl sulfate admixed with a minor proportion of a pharmaceutically acceptable film-forming, first polymer permeable to water and diltiazem, and a major proportion of a pharmaceutically acceptable film-forming, second polymer that is less permeable to water and diltiazem than the first polymer. The core and the coating layer both exclude organic acids. The composition of the coating layer as well as the proportion of core to coating layer are effective to permit release of the diltiazem allowing controlled absorption following oral administration.

Abstract: The invention relates to novel cosmetic or dermatological compositions, characterized in that they comprise, in a cosmetically acceptable support, at least one solution or one emulsion of at least one multiblock polycondensate whose chain consists of the repetition of at least one polysiloxane block and of at least one polyurethane and/or polyurea block; the said polyurethane and/or polyurea block also including ionizable groups and the said polycondensate being dissolved in an aqueous, organic or aqueous-organic solvent system. These compositions may be used in particular in the cosmetic field of hair care, make-up or skincare.

Abstract: The invention relates to a sweet of boiled sugar type exhibiting a rough texture intended for the treatment of halitosis as well as process for making the same and a method for treating halitosis using the same.

Abstract: A composition is disclosed comprising a polymer and a surfactant in a solvent exhibiting a common solubility for the polymer and the surfactant. The composition provides a dosage form for administering a drug over time.

Abstract: The present invention relates to a biodegradable hydrogel comprising bonds which are hydrolyzable under physiological conditions. More particularly, the hydrogel consists of two interpenetrating polymer networks interconnected to one another through hydrolyzable spacers. In addition, the invention relates to a method for the preparation of a hydrogel, wherein macromolecules, e.g., polymers which contain bonds which are hydrolyzable under physiological conditions, are cross-linked in an aqueous solution.

Abstract: Pharmaceutical formulations, and processes for making same, comprising an amino acid which is liable to formation of an undesirable lactam, and a stabilizer comprising a volatile alcohol; a non-volatile alcohol; a water immiscible liquid or solid; a liquid with a relatively low dielectric constant; a liquid surface active agent; a solid surface active agent; an antioxidant; a ketone; an aldehyde; a solid polyethylene glycol of high molecular weight; polyvinylpyrrolidone; a derived cellulose; silicon dioxide; or a combination thereof.

Abstract: A composition for facilitating delivery of biological agents, comprising a supramolecular complex including as constituents a block copolymer, having at least one nonionic, water soluble segment and at least one polyionic segment, and at least one charged surfactant having hydrophobic groups, the charge of the surfactant being opposite to that of the polyionic segment of the block copolymer. The constituents of the complex are bound by interaction between the opposite charges thereof and between surfactant hydrophobic groups. The complex may include an anionic surfactant having a biological activity, in which case the net charge of such anionic surfactant is no more than about 10.